<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938908</url>
  </required_header>
  <id_info>
    <org_study_id>97-01-104-18912</org_study_id>
    <nct_id>NCT04938908</nct_id>
  </id_info>
  <brief_title>Probiotic in Dry Eye Syndromes</brief_title>
  <official_title>Efficacy and Safety of Systemic and Ophthalmic Probiotic on Microbiota, Immunological and Clinical Outcomes of Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate efficacy and safety of systemic and ophthalmic probiotic from&#xD;
      bacterial lysate of Lactobacillus sakei on microbiota, immunological and clinical outcomes of&#xD;
      patients with Dry Eye Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Slit exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer test</measure>
    <time_frame>4 weeks</time_frame>
    <description>physical exam using Schirmer strip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface microbiota composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>measured by 16s rRNA method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Interleukin level</measure>
    <time_frame>4 weeks</time_frame>
    <description>measured by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Ophthalmic probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye/ 5 hours for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye/ 5 hours for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ophthalmic Probiotic</intervention_name>
    <description>Phospholipid from bacterial lysate of Lactobacillus sakei</description>
    <arm_group_label>Ophthalmic probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  M or F&#xD;
&#xD;
          -  18&lt;age&lt;60&#xD;
&#xD;
          -  BCVA&gt;=9/10&#xD;
&#xD;
          -  Signed informed consent, voluntary adherence to treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy/breastfeeding&#xD;
&#xD;
          -  Conjunctivitis&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Rheumatologic diseases including Sjogren's syndrome&#xD;
&#xD;
          -  Neurologic conditions, including stroke, Bell's palsy, Parkinson's, trigeminal nerve&#xD;
             problem&#xD;
&#xD;
          -  Refractive surgery (LASIK or PRK)&#xD;
&#xD;
          -  Other Eye Surgeries&#xD;
&#xD;
          -  HSV Keratitis&#xD;
&#xD;
          -  Medication/supplement use, including psychiatric medicines, OTC cold medicines,&#xD;
             anti-histamines, beta-blockers, pain relievers, sleeping pills, diuretics, Hormones&#xD;
             replacement, and oral contraceptives&#xD;
&#xD;
          -  Chemical splashes / injuries to the eyes&#xD;
&#xD;
          -  Contact lens use&#xD;
&#xD;
          -  Environmental (dusty, windy, hot/dry)&#xD;
&#xD;
          -  Any treatment for dry eye in previous 4 weeks (including lubricants, steroids,&#xD;
             cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mojtaba Heydari, M.D., Ph.D</last_name>
    <phone>+98 917 205 1798</phone>
    <email>mheydari@sums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Center for Traditional Medicine and History of Medicine-Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mojtaba Heydari</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

